Literature DB >> 28833375

Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion.

Meng K Wong1, Cedric C Y Ng2, Chik H Kuick3, Sze J Aw3,4, Vikneswari Rajasegaran2, Jing Q Lim2, Jain Sudhanshi3, Eva Loh3, Minzhi Yin5, Jing Ma5, Zhongde Zhang5, Prasad Iyer6, Amos H P Loh1,7,8, Derrick W Q Lian3,8, Shi Wang9, Shaun G H Goh9, Tse H Lim10, Alvin S T Lim10, Tony Ng11, Angela Goytain11, Alwin H L Loh4,8, Puay H Tan4,8, Bin T Teh2,8, Kenneth T E Chang1,3,8.   

Abstract

AIMS: Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignant tumour. The majority of CCSKs have internal tandem duplications (ITDs) of the BCOR gene, whereas a minority have the YWHAE-NUTM2 gene fusion. A third 'double-negative' (DN) category comprises CCSKs with neither BCOR ITDs nor YWHAE-NUTM2 fusion. The aim of this study was to characterise 11 histologically diagnosed CCSKs immunohistochemically (with CCND1, BCOR and CCNB3 stains) and genetically. METHODS AND
RESULTS: By next-generation sequencing, 10 cases (90.9%) had BCOR exon 15 ITDs, with positive BCOR immunoreactivity being found in four (36%) or eight (72%) cases, depending on the antibody clone. By reverse transcription polymerase chain reaction, none had the YWHAE-NUTM2 fusion. The DN case had a BCOR-CCNB3 fusion and strong nuclear CCNB3 and BCOR immunoreactivity. Quantitative polymerase chain reaction showed markedly elevated BCOR expression in this case, whereas BCOR ITD cases had lower levels of elevated BCOR expression.
CONCLUSIONS: The majority of the CCSKs in our cohort had BCOR ITDs, and none had the YWHAE-NUTM2 fusion. We verified the strong, diffuse cyclin D1 (CCND1) immunoreactivity in CCSKs described in recent reports. BCOR immunoreactivity was not consistently positive in all CCSKs with BCOR ITDs, and therefore cannot be used as a diagnostic immunohistochemical stain to identify BCOR ITD cases. The DN case was a BCOR-CCNB3 fusion sarcoma. BCOR-CCNB3 sarcoma is typically a primary bone sarcoma affecting male adolescents, and this is the first report of it presenting in a kidney of a young child as a CCSK. The full spectrum of DN CCSKs awaits more comprehensive characterisation.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  BCOR internal tandem duplication; CCNB3; clear cell sarcoma of kidney; cyclin D1 (CCND1); gene fusion; immunohistochemistry; paediatric renal tumours

Mesh:

Substances:

Year:  2017        PMID: 28833375     DOI: 10.1111/his.13366

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  Clear cell sarcoma of the kidney in children: a clinopathologic analysis of three cases.

Authors:  Shaohua Chen; Ming Li; Ran Li; Jintao Cao; Qiong Wu; Ting Zhou; Zhaogen Cai; Nan Li
Journal:  Int J Clin Exp Pathol       Date:  2020-04-01

2.  Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia.

Authors:  Pedram Argani; Bruce Pawel; Sara Szabo; Miguel Reyes-Múgica; Charles Timmons; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

3.  BCOR-CCNB3 fusion and BCOR internal tandem duplication in undifferentiated round cell sarcoma: a pathologic and molecular study of 5 cases.

Authors:  Yang Yang; Huijuan Shi; Jiaxin Zheng; Huabin Gao; Tiantian Zhen; Fenfen Zhang; Anjia Han
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

4.  Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.

Authors:  Pedram Argani; Yu-Chien Kao; Lei Zhang; Carlos Bacchi; Andres Matoso; Rita Alaggio; Jonathan I Epstein; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-12       Impact factor: 6.394

Review 5.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

6.  A Case Series of BCOR Sarcomas With a New Splice Variant of BCOR/CCNB3 Fusion Gene.

Authors:  Anastasios Kyriazoglou; Natalia Tourkantoni; Michalis Liontos; Flora Zagouri; Louisa Mahaira; Alexandra Papakosta; Dimitra Michali; Amalia Patereli; Kalliopi Stefanaki; Vasiliki Tzotzola; Evangelia Skoura; Margarita Baka; Sofia Polychronopoulou; Antonis Kattamis; Efthymios Dimitriadis
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma.

Authors:  Li Lei; Bradley A Stohr; Stacey Berry; Christina M Lockwood; Jessica L Davis; Erin R Rudzinski; Christian A Kunder
Journal:  Pract Lab Med       Date:  2020-05-16

8.  TLE1 Positive Clear Cell Sarcoma of the Kidney: A Case Report and Review of the Literature.

Authors:  Rana Naous
Journal:  Case Rep Pathol       Date:  2018-10-16

Review 9.  BCOR involvement in cancer.

Authors:  Annalisa Astolfi; Michele Fiore; Fraia Melchionda; Valentina Indio; Salvatore N Bertuccio; Andrea Pession
Journal:  Epigenomics       Date:  2019-05-31       Impact factor: 4.778

Review 10.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.